- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05605470
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
April 8, 2024 updated by: Technovalia, Pty Ltd
A Phase 2 Study to Evaluate the Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Authorized/Approved COVID-19 Vaccine
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous booster dose of any authorized/approved COVID-19 vaccine.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
This is a phase II, randomised open-label trial in which 150 healthy males and non-pregnant females aged 18-64 years, will be recruited from multi-sites in Australia.
This is a 2-part study (Part A and Part B).
In Part A, the randomisation will be a 2:1 design to receive either ChulaCov19 BNA159 vaccine or Comirnaty Pfizer/BNT vaccine.
In Part B, participants will receive only ChulaCov19 BNA159.2 (Bivalent, COMVIGEN) vaccine.
Participants in part A and B will be followed up using a combination of an-site and telephone visits for assessment of safety and immunogenicity for 6 months post-vaccination.
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Director Clinical Development
- Phone Number: +613 95979651
- Email: souadm@technovalia.com
Study Contact Backup
- Name: Clinical Team Manager; Clinical Project Manager
- Phone Number: +66817017165; +61437111458
- Email: vilasinee.y@bionet-asia.com; Rochellec@technovalia.com
Study Locations
-
-
Australian Capital Territory
-
Bruce, Australian Capital Territory, Australia, 2617
- Paratus research Canberra Clinic
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Paratus Clinical Research Western Sydney
-
Kanwal, New South Wales, Australia, 2259
- Paratus Clinical Research Central Coast
-
Westmead, New South Wales, Australia, 2145
- The Children's Hospital at Westmead Sydney
-
-
Queensland
-
Albion, Queensland, Australia, 4010
- Paratus Clinical Research- Brisbane Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Must be a male or female aged 18 - 64 (inclusive) at the time of enrolment
- Must have completed a primary course of 2 doses of any approved COVID-19 vaccine and 3 months or more have passed since receipt of last booster dose (1 or 2 prior booster doses for a total of 3 or 4 doses) as described in Table 1
- Must be able to communicate effectively with study personnel and considered reliable, willing, and cooperative in terms of compliance with the protocol requirements
- Participants must sign the written informed consent form prior to undertaking any protocol-related procedures
- SARS-CoV-2 rapid antigen test is negative at Day 1 (the day of receiving the study booster dose)
- Does not intend to receive any other authorized/approved COVID-19 vaccine at the time of enrolment and up to 3 months of the study
- Males must be surgically sterile (>30 days since vasectomy with no viable sperm), practice true abstinence or, if engaged in sexual relations with a female of childbearing potential, the participants and their partner must use an acceptable, highly effective, dual contraceptive method* from Screening and for a period of at least 90 days after vaccination
A female participant is eligible if she is not pregnant, or breastfeeding indicated by one of the following conditions:
- With childbearing potential: she agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the study intervention administration until at least 90 days after the study intervention administration, or
- With non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. If the participant is < 1 year post-menopausal, an FSH test may be conducted to establish childbearing potential.
- Participants must be in general good health* based on medical history and physical examination, as determined by the PI at Screening.
- Participants must agree to refrain from donating blood, plasma, ova, sperm, or organs during the whole study.
Exclusion Criteria:
- History of a systemic hypersensitivity or life-threatening reaction to a vaccine containing any of the same or similar substances.
- History of test-confirmed by PCR or rapid antigen test to SARS-CoV-2 COVID-19 infection within 3 months prior to randomisation.
- Presence of clinically significant medical history*, unstable chronic or acute disease that, in the opinion of the PI, may increase the risk of exposure to the investigational vaccine
- History of having any significant side effects after receipt of any other COVID-19 vaccine eg. endocarditis, pericarditis or myocarditis. History of any severe reactogenic side effects or other medical illness that were thought to be associated with vaccine.
- Presence of an acute illness* or with fever at 38.00 C or more within 72 hours prior to vaccination.
- Bleeding disorders or taking an anticoagulant or anti-platelet agent that may contraindicate for intramuscular injection based on Investigator's judgment
- Inadequate venous access to allow the collection of blood samples.
- Received any prophylactic or therapeutic vaccine, biologic product, device or blood product, within 4 weeks of vaccination or 5 half-lives (whichever is longer) or anticipate doing so in the follow-up period defined for this study. For influenza vaccine, however, can be administered up to 14 days prior to randomization and following Visit 3 (Day 29+3) blood sample collection.
- History of ever had an anaphylaxis reaction to food, medication, or vaccination.
- Participant is immunosuppressed as caused by disease or immunosuppressive therapy or anticipated need to use of any chemotherapy or immunosuppressive agents* within the next 6 months.
- Participation in any of the other investigational trials of vaccines, therapeutic, or medical devices 12 weeks before or during the 6 months of this study.
- Received immunoglobulins and/or any blood or blood products within 3 months before vaccination day or plans to receive any blood or blood products at any time during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Arm 1 (1 dose of ChulaCov19 BNA159 vaccine)
Participants will be randomized to receive ChulaCov19 BNA159 vaccine (50 mcg) given by IM (n=55)
|
Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
|
Active Comparator: Part A: Arm 2 (one dose of active comparator vaccine)
Participants will be randomized to receive Comirnaty® (Pfizer/BNT) vaccine (30 mcg) given by IM (n=25)
|
Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
|
Experimental: Part B: Arm 3 (one dose of COMVIGEN vaccine)
Participants will be randomized to receive ChulaCov19 BNA159.2 (COMVIGEN) vaccine (50 mcg) given by IM (n=70)
|
Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A and Part B: Numbers and percentage of participants with immediate adverse events
Time Frame: within 30 minutes post vaccination
|
Numbers and percentage of participants who have had immediate post-immunization reactions within 30 minutes post- vaccination
|
within 30 minutes post vaccination
|
Part A and Part B: Numbers and percentage of participants with solicited local or systemic reactions
Time Frame: within 7-day post-vaccination
|
Numbers and percentage of participants who have had solicited local or systemic reactions within 7-day post-vaccination
|
within 7-day post-vaccination
|
Part A and Part B: Numbers and percentage of participants with adverse events (AEs)
Time Frame: 28-day post-vaccination
|
Numbers and percentage of participants who have had adverse events (AEs) within 28-day post-vaccination
|
28-day post-vaccination
|
Part A and Part B:Numbers and percentage of participants with serious adverse events (SAEs), medically attended adverse events (MAAEs) and New Onset Chronic Medical Condition (NOCMCs)
Time Frame: 6 months post-vaccination
|
Numbers and percentage of participants who have had SAEs, MAAEs, NOCMCs within 6 months post-vaccination
|
6 months post-vaccination
|
Geometric mean titres (GMTs) of SARS-CoV-2-specific serum neutralising antibody as measured by psVNT-50 against wild type and/or Omicron BA.4/BA.5
Time Frame: Baseline, 28-day post-vaccination
|
GMTs and their 95%CI of SARS-CoV-2-specific serum neutralising antibody as measured by psVNT-50 against wild type (Part A and B) and/or Omicron BA.4/BA.5 (Part B) will be reported at baseline (before vaccination) and 28 days post-vaccination.
|
Baseline, 28-day post-vaccination
|
Geometric mean fold rises (GMFRs) of SARS-CoV-2-specific serum neutralising titres as measured by psVNT-50 against wild type and/or Omicron BA.4/BA.5
Time Frame: Baseline, 28-day post-vaccination
|
GMFRs and their 95%CI of SARS-CoV-2-specific serum neutralising titres as measured by psVNT-50 against wild type (Part A and B) and/or Omicron BA.4/BA.5 (Part B) will be reported from baseline to 28 days post-vaccination.
|
Baseline, 28-day post-vaccination
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV-2-specific serum neutralising antibody titres as measured by psVNT-50 against wild type and/or Omicron BA.4/BA.5
Time Frame: 28 days post-vaccination.
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV-2-specific serum neutralising antibody titres as measured by psVNT-50 against wild type (Part A and B) and/or Omicron BA.4/BA.5 (Part B) will be reported at 28 days post-vaccination.
|
28 days post-vaccination.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GMTs of SARS-CoV-2-specific serum neutralising antibody as measured by psVNT-50 against Omicron BA.4/BA.5 and/or other clinically relevant variants of concerns (VOCs)
Time Frame: Baseline, 28-day post-vaccination
|
GMTs and their 95%CI of SARS-CoV-2-specific serum neutralising antibody as measured by psVNT-50 against Omicron BA.4/BA.5 (Part A) and/or other clinically relevant VOCs (Part A and B) will be reported at baseline (before vaccination) and 28 days post-vaccination.
|
Baseline, 28-day post-vaccination
|
GMFRs of SARS-CoV-2-specific serum neutralising titres as measured by psVNT-50 against Omicron BA.4/BA.5 and/or other clinically relevant VOCs
Time Frame: Baseline, 28-day post-vaccination
|
GMFR and their 95%CI of SARS-CoV-2-specific serum neutralising titres as measured by psVNT-50 against Omicron BA.4/BA.5 (Part A) and/or other clinically relevant VOCs (Part A and B) will be reported from baseline to 28 days post-vaccination.
|
Baseline, 28-day post-vaccination
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV-2-specific serum neutralising antibody titres as measured by psVNT-50 against Omicron BA.4/BA.5 and/or other clinically relevant VOCs
Time Frame: 28-day post-vaccination
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV-2-specific serum neutralising antibody titres as measured by psVNT-50 against Omicron BA.4/BA.5 (Part A) and/or other clinically relevant VOCs (Part A and B) will be reported at 28 days post-vaccination.
|
28-day post-vaccination
|
GMTs of SARS-CoV-2-specific serum neutralising antibody as measured by MicroVNT-50 against wild type
Time Frame: Baseline, 28-day post-vaccination
|
Part A and Part B: GMTs and their 95%CI of SARS-CoV-2-specific serum neutralising antibody as measured by MicroVNT-50 against wild type will be reported at baseline (before vaccination) and 28 days post-vaccination.
|
Baseline, 28-day post-vaccination
|
GMFRs of SARS-CoV-2-specific serum neutralising titres as measured by MicroVNT-50 against wild type
Time Frame: Baseline to 28 days post-vaccination.
|
Part A and Part B: GMFR and their 95%CI of SARS-CoV-2-specific serum neutralising titres as measured by MicroVNT-50 against wild type will be reported from baseline to 28 days post-vaccination.
|
Baseline to 28 days post-vaccination.
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV-2-specific serum neutralising antibody titres as measured by MicroVNT-50 against wild type
Time Frame: 28 days post-vaccination
|
Part A and Part B: Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV-2-specific serum neutralising antibody titres as measured by MicroVNT-50 against wild type will be reported at 28 days post-vaccination.
|
28 days post-vaccination
|
GMTs of SARS-CoV2-RBD-binding (anti-RBD) and Spike-binding (anti-S) IgG antibodies as measured by ELISA against wild type and Omicron.
Time Frame: Baseline and 28 days post-vaccination.
|
GMTs and their 95%CI of anti-RBD and anti-S IgG antibodies as measured by ELISA against wild type (Part A and B) and Omicron (Part B) will be reported at baseline (before vaccination) and 28 days post-vaccination.
|
Baseline and 28 days post-vaccination.
|
GMFRs of SARS-CoV2-RBD-binding (anti-RBD) and Spike-binding (anti-S) IgG antibodies as measured by ELISA against wild type and Omicron.
Time Frame: Baseline to 28 days post-vaccination.
|
GMFR and their 95%CI of anti-RBD and anti-S IgG antibodies as measured by ELISA against wild type (Part A and B) and Omicron (Part B) will be reported from baseline to 28 days post-vaccination.
|
Baseline to 28 days post-vaccination.
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of SARS-CoV2-RBD-binding (anti-RBD) and Spike-binding (anti-S) IgG antibodies as measured by ELISA against wild type and Omicron.
Time Frame: 28 days post-vaccination
|
Percentage of participants who achieved a greater than or equal to 4-fold rise from before vaccination of anti-RBD and anti-S IgG antibodies as measured by ELISA against wild type (Part A and B) and Omicron (Part B) will be reported at 28 days post-vaccination
|
28 days post-vaccination
|
Geometric mean (GM) and/or median number of SARS-CoV2-specific T-cell responses (spot-forming cells (SFC) per 1 million PBMCs) measured by IFNγ-ELISpot assay against wild-type peptides
Time Frame: Baseline and 28 days post-vaccination.
|
Part A and Part B: GM and/or median number of SFC per 1 million PBMCs measured by IFNγ-ELISpot assay against wild-type peptides will be reported at baseline (before vaccination) and 28 days post-vaccination
|
Baseline and 28 days post-vaccination.
|
GMFRs of number of SFC per 1 million PBMCs measured by IFNγ-ELISpot assay against wild-type peptides
Time Frame: Baseline to 28 days post-vaccination.
|
Part A and Part B: GMFR and their 95%CI of number of SFC per 1 million PBMCs measured by IFNγ-ELISpot assay against wild-type peptides will be reported from baseline to 28 days post-vaccination.
|
Baseline to 28 days post-vaccination.
|
GM and/or median number of % Spike specific CD4 and CD8 T-cells as measured by Intracellular Cytokine Staining (ICS) assay
Time Frame: Baseline and 28 days post-vaccination
|
Part A and Part B: GM and/or median number of % Spike specific CD4 and CD8 T-cells as measured by ICS assay (from the first 25 subjects from the ChulaCov19 group, the comparator group and COMVIGEN) will be reported at baseline (before vaccination) and 28 days post-vaccination.
|
Baseline and 28 days post-vaccination
|
GMFR of % Spike-specific CD4 and CD8 T-cells as measured by ICS assay
Time Frame: Baseline to 28 days post-vaccination.
|
Part A and Part B: GMFR of % Spike-specific CD4 and CD8 T-cells as measured by ICS assay (from the first 25 subjects from the ChulaCov19 group, the comparator group and COMVIGEN) will be reported from baseline to 28 days post-vaccination.
|
Baseline to 28 days post-vaccination.
|
GM and/or median number of Th1/Th2 ratio as measured by ICS assay
Time Frame: Baseline and 28 days post-vaccination
|
Part A and Part B: GM and/or median number of Th1/Th2 ratio as measured by ICS assay (from the first 25 subjects from the ChulaCov19 group, the comparator group and COMVIGEN) will be reported at baseline (before vaccination) and 28 days post-vaccination.
|
Baseline and 28 days post-vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kiat Ruxrunghtam, MD, Chulalongkorn University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 19, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
October 30, 2022
First Submitted That Met QC Criteria
October 30, 2022
First Posted (Actual)
November 4, 2022
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TVL-ChulaVac005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19, SARS CoV 2 Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
University of MelbourneThe George Institute; The University of Queensland; The Peter Doherty Institute... and other collaboratorsRecruitingSARS-CoV-2 Infection (COVID-19)Australia
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
Stanford UniversityPfizerCompletedLong COVID | Post-acute Sequelae of SARS-CoV-2 InfectionUnited States
-
The Board of MedicineApollo Neuroscience, Inc.RecruitingPost-acute Sequelae of SARS-COV-2 InfectionUnited States
-
Ono Pharmaceutical Co. LtdCompletedSARS-CoV-2 Infection (COVID-19)Japan
-
Rohto Pharmaceutical Co., Ltd.CompletedSARS-CoV-2 Infection( COVID-19 )Japan
-
PfizerCompletedCovid-19 | Immunocompromised | Breakthrough Infection | SARS-COV-2 Infection | SARS-COV-2 | ImmunosuppressedUnited States
-
Dr. Ferrer BioPharmaClinica Union Medica Del Norte, S.A.S., Santiago, República DominicanaActive, not recruitingAccelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis (ACCROS-R)COVID-19 | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Respiratory Infection | SARS CoV 2 Infection | COVID-19 PandemicDominican Republic
-
Tonix Pharmaceuticals, Inc.CompletedCOVID-19 | Long COVID | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Long Haul COVIDUnited States
Clinical Trials on ChulaCov19 BNA159 vaccine (50 mcg)
-
Chulalongkorn UniversityBioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaboratorsRecruitingSafety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditionsThailand
-
Chulalongkorn UniversityNational Vaccine Institute, Thailand; Chula Vaccine Research Center (ChulaVRC)... and other collaboratorsCompleted
-
MedImmune LLCCompletedRespiratory Syncytial Virus (RSV)United States
-
Crucell Holland BVNational Institute of Allergy and Infectious Diseases (NIAID); Beth Israel...Completed
-
DBV TechnologiesCompletedPeanut AllergyUnited States, Netherlands, France, Canada, Poland
-
Chulalongkorn UniversityHIV-NAT, Thai Red Cross - AIDS Research Centre; Chula Clinical Research Center...RecruitingSafety of a Single Dose of COMVIGEN Vaccine | Reactogenicity of a Single Dose of COMVIGEN Vaccine | Immunogenicity of a Single Dose of COMVIGEN Vaccine | Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine | Reactogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine | Immunogenicity...Thailand
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Poland
-
Sunovion Respiratory Development Inc.Completed
-
Sunovion Respiratory Development Inc.Completed
-
Radius Health, Inc.Nordic Bioscience A/SCompletedPost Menopausal OsteoporosisPoland, Denmark, United States, Estonia